COYA (Coya Therapeutics) ROCE %: -60.28% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COYA Coya Therapeutics Inc COYA
49 GF Score
Price $4.39
GF Value $6.54
Valuation Significantly Undervalued
View Full Analysis

What is Coya Therapeutics ROCE %?

Coya Therapeutics COYA -3.10% 49 ROCE % is -60.28% as of Jun. 2026. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Coya Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2026 was -60.28%.

Coya Therapeutics  (NAS:COYA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Coya Therapeutics ROCE % Related Terms

Coya Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Coya Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coya Therapeutics ROCE % Chart

Coya Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -81.53 -238.85 -38.76 -44.96 -53.32

Coya Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.44 -33.95 -66.59 -65.16 -60.28
COYA
49GF Score
Coya Therapeutics Inc COYA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coya Therapeutics ROCE % Calculation

Coya Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-22.555/( ( (44.347 - 3.824) + (49.95 - 5.872) )/ 2 )
=-22.555/( (40.523+44.078)/ 2 )
=-22.555/42.3005
=-53.32 %

Coya Therapeutics's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-28.188/( ( (53.271 - 3.547) + (47.308 - 3.512) )/ 2 )
=-28.188/( ( 49.724 + 43.796 )/ 2 )
=-28.188/46.76
=-60.28 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -60.28% mean?
Coya Therapeutics (COYA) has a ROCE % of -60.28% as of Jun. 2026.
Is Coya Therapeutics' ROCE % too high?
Coya Therapeutics' current ROCE % is -60.28%. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' ROCE % compare to ONCY and GUTS?
Coya Therapeutics' ROCE % of -60.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Coya Therapeutics's current ROCE % is -60.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current ROCE % is -60.28%. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current ROCE % is -60.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coya Therapeutics (COYA) Overvalued in 2026?

Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued. The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54. GuruFocus considers Coya Therapeutics to be Significantly Undervalued.

Key valuation signals for COYA:

  • ROCE %: -60.28%
  • GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
  • GF Score™: 49/100

No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coya Therapeutics Business Description

Address 5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score

Get the complete analysis for COYA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.39
Price
$6.54
GF Value